World Bioengineered Protein Drugs Market - Opportunities and Forecasts, 2017-2023

Pharmaceuticals	LI 171462	Pages: NA	Formats*:
Nov 2017 \| 200 Views	Charts: NA	Tables: NA

Proteins play a crucial role in maintaining both structural and functional aspects of an individual organism. Long chain of amino acids makes up a protein molecule and regulates all biological functions such as metabolic reactions, DNA replication and other vital expressional functions in the body. Bioengineered proteins are designed as the fundamental participants in all biological processes, represent as powerful therapeutic agents and include a broad range of products such as growth factors, hormones, vaccines, monoclonal antibodies, cytokines and few others. These special drugs are gaining attention across pharmaceutical industries due to their specificity, safety, bioreactivity and success rate in treating life-threatening diseases and injuries. Rising prevalence of diseases such as cancer, diabetes, heart diseases, asthma and others is the crucial driver of the bioengineered protein drugs market.

Other factors propelling the growth of this market include technological advancement in manufacturing bioengineering drug proteins, targeted drug delivery methods for efficient treatment and rising expenditure on healthcare. However, high cost associated with the bioengineered protein drugs limit the growth of the market. Moreover, complications involved while treating certain diseases with bioengineered drugs obstruct the growth of bioengineered protein drugs globally.

Delivering these biologically active proteins to the target organs and tissues is a major issue. Bioengineered protein drugs are achieving significant progression as novel treatment in number of diseases such as chronic diseases, cancer, asthma and others. Thus, efficient drug delivery methods using technologically advanced vehicles such as micelles, liposomes and hydrogels are contributing toward the growth of this market.

The report segments the bioengineered protein drugs market on the basis of drug types, diseases, technologies, drug delivery methods and geography. On the basis of drug types, the market is further segmented into recombinant protein drugs, peptide hormones, vaccines, therapeutic enzymes, monoclonal antibodies, cytokines, replacement proteins, peptide antibiotics and blood products. Monoclonal antibodies type is the most attractive drug type owing to its increased usage in therapeutics for autoimmune diseases, cancer and inflammatory diseases. According to the diseases segment, the market has been classified into diabetes, cancer, skin diseases, blood disorders, heart diseases, neurodegenerative diseases, respiratory diseases, infectious diseases, congenital diseases, autoimmune disorders, arthritis and others.

Based on technology, the market is further segmented into fractionation, bioreactors and microbial cell fermentation, genetic engineering, genetically modified organisms (GMOs), pharming, bioengineered protein drugs produced by transgenic microorganisms, plants and animals, cell culture and others. The advancement in manufacturing technologies such as GMOs and cell cultures are boosting the market growth. Based on drug delivery methods, the market has been classified into traditional methods and novel approaches. Geographic breakdown and deep analysis of each of the aforesaid segments has been included for North America, Europe, Asia-Pacific and LAMEA. North America dominate the bioengineered protein drugs market and U.S. is the leading country in this market due to the high technological advancements and extensive R&D practiced for manufacturing bioengineered protein drugs.

Comprehensive competitive analysis and profiles of major market players such as Abbott Laboratories, Amgen, Baxter Healthcare, Bayer Healthcare Pharmaceuticals, Eli Lilly and Co., GlaxoSmithKline, Fresenius Kabi USA, Hoffman-la-Roche, Johnson & Johnson and Merck & Co. Inc., have been provided in the report.

KEY MARKET BENEFITS:

Comprehensive analysis of factors that drive and restrict the growth of the global bioengineered protein drugs market is provided.
The projections in this report are made by analyzing the current market trends and the market potential for the forecast period of 2014-2020, in terms of value.
A comprehensive analysis of drug types, diseases, technologies, drug delivery methods and geography segments enable the identification of growth opportunities within the global bioengineered protein drugs market
Competitive intelligence (of leading manufacturers of bioengineered protein drugs) helps in understanding the competitive scenario across geographies
SWOT analysis of the key market players is provided to illustrate the business strategies adopted by the key companies
The report provides quantitative analysis of the current market and estimations through 20142020 that help in identifying the prevailing market opportunities to capitalize on

KEY MARKET SEGMENTS:

The global bioengineered protein drugs market is segmented into drug types, diseases, technologies, drug delivery methods and geography segments.

Bioengineered Protein Drugs Market By Drugs Type

Recombinant protein drugs
Peptide hormones
- Growth hormones
- Insulin
- Erythropoietin
- Luteinizing hormones and follicle stimulating hormones
Vaccines
- Toxoid
- Subunit/conjugate
- Inactivated/killed vaccines
- Live attenuated vaccines
Therapeutic enzymes
- Metabolic enzymes
- Digestive enzymes
- Other enzymes
Monoclonal antibodies
Cytokines
- Interleukins
- Interferons
- Colony stimulating factors
Replacement proteins
Peptide antibiotics
Blood products
- C1 esterase inhibitor
- Antithrombin
- Thrombin
- Immune globulins
- Coagulation factors
- Alpha 1-protease inhibitor

Bioengineered Protein Drugs Market By Diseases

Diabetes
Cancer
Skin diseases
Blood disorders
Heart diseases
Neurodegenerative diseases
Respiratory diseases
Infectious diseases
Congenital diseases
Autoimmune disorders
Arthritis
Others

Bioengineered Protein Drugs Market By Technology

Fractionation
Bioreactors and microbial cell fermentation
Genetic engineering
Genetically modified organisms
Pharming
Bioengineered protein drugs produced by transgenic microorganisms, plants and animals
Cell culture
Others

Bioengineered Protein Drugs Market By Drug Delivery Methods

Traditional methods
- Oral
- Transmucosal
- Topical
- Parenteral
- Inhalation
Novel approaches according to recent research
- Micelles
- Microspheres
- Liposomes
- Microemulsions
- Nanoparticles
- Hydrogels
- Prodrug
- Thin-film drug delivery

Bioengineered Protein Drugs Market By Geography

North America
Europe
Asia-Pacific
LAMEA

Enquiry About Report

Please input above shown text into input box
or click refresh

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

License Type

Data Pack

Single User PDF

Five User Online/PDF

Enterprise Online/PDF

LICENSE INFO

Users/Sharing

Restricted to one authorized user

Limited to 5 authorized users

Unlimited within company / enterprise

Printing

One Print only